Cost-Effectiveness Analysis of Cytoreductive Surgery and HIPEC Compared With Systemic Chemotherapy in Isolated Peritoneal Carcinomatosis From Metastatic Colorectal Cancer
- 75 Downloads
Cost-effectiveness evaluations of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of peritoneal carcinomatosis (PC) from metastatic colorectal cancer (mCRC) in the United States are lacking.
The authors developed a Markov model to evaluate the cost-effectiveness of CRS/HIPEC compared with systemic chemotherapy for isolated PC from mCRC from a societal perspective in the United States. The systemic treatment regimens consisted of FOLFOX, FOLFIRI, bevacizumab, cetuximab, and pantitumumab. The model inputs including costs, probabilities, survival, progression, and utilities were taken from the literature. The cycle length for the model was 2 weeks, and the time horizon was 7 years. A discount rate of 3% was applied. The model was tested for internal and external validation, and robustness was established with univariate sensitivity and probabilistic sensitivity analyses (PSA). The primary outcomes were total costs, quality-adjusted life-years (QALYs), life-years (LYs), and incremental cost-effectiveness ratio (ICER). A willingness-to-pay (WTP) threshold of $100,000 per QALY was assumed.
The ICER for treatment with CRS/HIPEC compared with systemic chemotherapy was $91,034 per QALY gained ($74,098 per LY gained). The univariate sensitivity analysis showed that the total costs for treatment with CRS/HIPEC had the largest effect on the calculated ICER. The CRS/HIPEC treatment was a cost-effective strategy during the majority of simulations in the PSA. The average ICER for 100,000 simulations in the PSA was $70,807 per QALY gained. The likelihood of CRS/HIPEC being a cost-effective strategy at the WTP threshold was 87%.
The CRS/HIPEC procedure is a cost-effective treatment for isolated PC from mCRC in the United States.
- 6.Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737–43. https://doi.org/10.1200/jco.2003.04.187.CrossRefGoogle Scholar
- 7.Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ III. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010;116:3756–62. https://doi.org/10.1002/cncr.25116.CrossRefGoogle Scholar
- 9.Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284–92. https://doi.org/10.1200/jco.2004.10.012.CrossRefGoogle Scholar
- 10.Bijelic L, Yan TD, Sugarbaker PH. Treatment failure following complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from colorectal or appendiceal mucinous neoplasms. J Surg Oncol. 2008;98:295–9. https://doi.org/10.1002/jso.21084.CrossRefGoogle Scholar
- 11.Turaga K, Levine E, Barone R, et al. Consensus guidelines from the American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol. 2013;21:1501–5. https://doi.org/10.1245/s10434-013-3061-z.CrossRefGoogle Scholar
- 13.Esquivel J, Piso P, Verwaal V, et al. American Society of Peritoneal Surface Malignancies opinion statement on defining expectations from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer. J Surg Oncol. 2014;110:777–8. https://doi.org/10.1002/jso.23722.CrossRefGoogle Scholar
- 15.Chua TC, Martin S, Saxena A, et al. Evaluation of the cost-effectiveness of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (peritonectomy) at the St George Hospital Peritoneal Surface Malignancy Program. Ann Surg. 2010;251:323–9. https://doi.org/10.1097/sla.0b013e3181c9b53c.CrossRefGoogle Scholar
- 20.Centers for Medicare and Medicaid Services. 2017. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/PFS-Federal-Regulation-Notices-Items/CMS-1654-F.html. Accessed 25 Feb 2018.
- 21.Centers for Disease Control and Prevention. 2017. https://www.cdc.gov/nchs/fastats/body-measurementshtm. Accessed 25 Feb 2018.
- 22.Centers for Medicare and Medicaid Services. 2017. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/. Accessed 25 Feb 2018.
- 23.Dindo D, Demartines N, Clavien P-A. Classification of surgical complications. Ann Surg. 2004;240:205–13. https://doi.org/10.1097/01.sla.0000133083.54934.ae.CrossRefGoogle Scholar
- 27.Ara R, Brazier J. Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient-level data are not available). Value Health. 2008;11:1131–43. https://doi.org/10.1111/j.1524-4733.2008.00352.x.CrossRefGoogle Scholar
- 28.Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-Year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15:2426–32. https://doi.org/10.1245/s10434-008-9966-2.CrossRefGoogle Scholar
- 29.Pietro F Bagnoli, Cananzi FCM, Brocchi A, et al. Peritonectomy and hyperthermic intraperitoneal chemotherapy: cost analysis and sustainability. Eur J Surg Oncol. 2015;41:386–91. https://doi.org/10.1016/j.ejso.2014.12.004.
- 31.Naffouje SA, O’Donoghue C, Salti GI. Evaluation of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a community setting: a cost-utility analysis of a hospital’s initial experience and reflections on the health care system. J Surg Oncol. 2016;113:544–7. https://doi.org/10.1002/jso.24162.CrossRefGoogle Scholar
- 32.Squires MH, Staley CA, Knechtle W, et al. Association between hospital finances, payer mix, and complications after hyperthermic intraperitoneal chemotherapy: deficiencies in the current healthcare reimbursement system and future implications. Ann Surg Oncol. 2015;22:1739–45. https://doi.org/10.1245/s10434-014-4025-7.CrossRefGoogle Scholar
- 33.Tentes AA, Pallas N, Korakianitis O, et al. The cost of cytoreductive surgery and perioperative intraperitoneal chemotherapy in the treatment of peritoneal malignancy in one Greek institute. J BUON. 2012;17:776–80.Google Scholar
- 35.NCCN Guidelines–Colon Cancer. Plymouth Meeting, PA: Harborside Press; 2017. pp. 1–143.Google Scholar
- 36.Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18:1182–91. https://doi.org/10.1016/s1470-2045(17)30422-9.CrossRefGoogle Scholar
- 37.Klaver YLB, Chua TC, Verwaal VJ, de Hingh IHJT, Morris DL. Secondary cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal recurrence of colorectal and appendiceal peritoneal carcinomatosis following prior primary cytoreduction. J Surg Oncol. 2013;107:585–90. https://doi.org/10.1002/jso.23303.CrossRefGoogle Scholar
- 41.Quenet F, Elias D, Roca L, et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol. 2018;36(18 Suppl):3503. https://doi.org/10.1200/jco.2018.36.18_suppl.lba3503.
- 42.Esquivel J, Lowy AM, Markman M, et al. The American Society of Peritoneal Surface Malignancies (ASPSM) multiinstitution evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1013 Patients with colorectal cancer with peritoneal carcinomatosis. Ann Surg Oncol. 2014;21:4195–201. https://doi.org/10.1245/s10434-014-3798-z.CrossRefGoogle Scholar
- 45.Kianmanesh R, Scaringi S, Sabate J-M, et al. Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases. Ann Surg. 2007;245:597–603. https://doi.org/10.1097/01.sla.0000255561.87771.11.CrossRefGoogle Scholar
- 46.Hinkle NM, MacDonald J, Sharpe JP, Dickson P, Deneve J, Munene G. Cytoreduction with hyperthermic intraperitoneal chemotherapy: an appraisal of outcomes and cost at a newly established peritoneal malignancy program. Am J Surg. 2016;212:413–8. https://doi.org/10.1016/j.amjsurg.2016.01.022.CrossRefGoogle Scholar
- 51.Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. The Lancet. 2013;381:303–12. https://doi.org/10.1016/s0140-6736(12)61900-x.CrossRefGoogle Scholar